Ferrer’s constant commitment to innovation means that a strategy of alliances and collaboration with public research bodies and prestigious biotech companies is essential.

Ferrer - CNIC

The Spanish National Centre for Cardiovascular Research (CNIC) is a public institution connected to the Carlos III Health Institute, which, under the leadership of its General Director, the distinguished cardiologist Dr. Valentin Fuster, has become a leading international research organization. Its mission is to undertake research into cardiovascular diseases with the aim of translating its expertise into clinical excellence, in order to prioritise prevention and promote health.

The CNIC and Ferrer, with the backing of the World Heart Federation, has developed the world’s first polypill for the secondary prevention of cardiovascular accidents in patients already undergoing treatment. It presents an important galenic innovation which ensures the stability and non-interaction of its three components.

It represents a significant advance in the worldwide treatment of cardiovascular diseases. The objective is to reduce the risk of suffering a second cardiovascular event. It provides medical professionals with a new therapeutic alternative, of proven efficacy, to improve patient adherence. Furthermore, ensuring affordable patient access to the treatment is one of the pillars of the CNIC-Ferrer project.

Ferrer - Alexza

Alexza is a pharmaceutical company based in the United States dedicated to the research, development and commercialization of novel proprietary products for the treatment of acute and intermittent conditions.

The company's innovative products are based on the proprietary Staccato® system, an inhaler which vaporizes excipient-free drugs, achieving pharmacokinetic properties similar to intravenous administration and rapid systemic effects.

Adasuve® is designed for the rapid treatment of mild to moderate agitation in adults with schizophrenia or bipolar disorder, by combining the Staccato system with loxapine, an antipsychotic drug currently available in various formulations.


Is an accelerator led by the University of Barcelona and Ferrer. It is made up of eighteen institutions in the health field: two universities, twelve biomedical research institutes and private foundations and four companies.

The ADVANCECAT project provides an organizational structure that accelerates the development of new advanced therapy drugs by bringing together both the public and private sectors. The goal is to better manage resources and to boost the Catalan health system.

The project also aims to strengthen the Catalan industrial sector by encouraging the identification of mechanisms and protocols for the industrial production of these drugs. It promotes the interaction of research centers and hospitals with businesses involved in this type of therapy. This will facilitate the rapid transition of these new drugs into the healthcare system.

The consortium has an initial budget of more than 2.8 million euros, of which around one million euros are co-financed by the Catalan Government’s Business Competitiveness Agency (ACCIÓ) and the European Union’s European Regional Development Fund (ERDF/FEDER) Catalonia 2014-2020.


Our aim is to establish long-term relationships with biotechnology and biopharmaceutical companies in our strategic therapeutic areas.